These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32735501)

  • 21. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Haycox A; Armand C; Murteira S; Cochran J; François C
    Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pramipexole for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002261. PubMed ID: 10908540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
    Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
    Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study.
    Lieberman A; Ranhosky A; Korts D
    Neurology; 1997 Jul; 49(1):162-8. PubMed ID: 9222185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
    Shannon KM; Bennett JP; Friedman JH
    Neurology; 1997 Sep; 49(3):724-8. PubMed ID: 9305331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek K; Jennings D; Seibyl J
    Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study.
    Ning H; Zhou H; Ren J; Zhou G; Yang N; Wang Z; Yuan C; Tian Z; Chen J; Shen L; Zheng H; Zhao Y; Wang H; Liu W; Liu Z
    J Transl Med; 2022 Aug; 20(1):357. PubMed ID: 35962349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of pramipexole in the management of Parkinson's disease.
    Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
    CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
    Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole for the treatment of early Parkinson's disease.
    Perez-Lloret S; Rey MV; Ratti L; Rascol O
    Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.